<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Andy Haegeman</style></author><author><style face="normal" font="default" size="100%">Ilse De Leeuw</style></author><author><style face="normal" font="default" size="100%">Saduakassova, Meruyert</style></author><author><style face="normal" font="default" size="100%">Willem Van Campe</style></author><author><style face="normal" font="default" size="100%">Laetitia Aerts</style></author><author><style face="normal" font="default" size="100%">Wannes Philips</style></author><author><style face="normal" font="default" size="100%">Sultanov, Akhmetzhan</style></author><author><style face="normal" font="default" size="100%">Laurent Mostin</style></author><author><style face="normal" font="default" size="100%">Kris De Clercq</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">The Importance of Quality Control of LSDV Live Attenuated Vaccines for Its Safe Application in the Field.</style></title><secondary-title><style face="normal" font="default" size="100%">Vaccines (Basel)</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Lumpy skin disease</style></keyword><keyword><style  face="normal" font="default" size="100%">Quality Control</style></keyword><keyword><style  face="normal" font="default" size="100%">recombinant</style></keyword><keyword><style  face="normal" font="default" size="100%">vaccine</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2021 Sep 13</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">9</style></volume><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;Vaccination is an effective approach to prevent, control and eradicate diseases, including lumpy skin disease (LSD). One of the measures to address farmer hesitation to vaccinate is guaranteeing the quality of vaccine batches. The purpose of this study was to demonstrate the importance of a quality procedure via the evaluation of the LSD vaccine, Lumpivax (Kevevapi). The initial PCR screening revealed the presence of wild type LSD virus (LSDV) and goatpox virus (GTPV), in addition to vaccine LSDV. New phylogenetic PCRs were developed to characterize in detail the genomic content and a vaccination/challenge trial was conducted to evaluate the impact on efficacy and diagnostics. The characterization confirmed the presence of LSDV wild-, vaccine- and GTPV-like sequences in the vaccine vial and also in samples taken from the vaccinated animals. The analysis was also suggestive for the presence of GTPV-LSDV (vaccine/wild) recombinants. In addition, the LSDV status of some of the animal samples was greatly influenced by the differentiating real-PCR used and could result in misinterpretation. Although the vaccine was clinically protective, the viral genomic content of the vaccine (being it multiple Capripox viruses and/or recombinants) and the impact on the diagnostics casts serious doubts of its use in the field.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">9</style></issue></record></records></xml>